GLP1R and diabetic foot: Werkman et al. have conducted a retrospective population-based cohort study on over 70,000 patients with T2D with the aim of investigating the risk of lower-limb amputations and diabetic foot ulcers with SGLT2i use and GLP-1 RA vs. sulfonylureas.